TIDMOBD
Oxford BioDynamics PLC
09 April 2021
Oxford BioDynamics signs lease for new lab and office space
at Oxford Business Park, supporting expanded strategy
Oxford, UK - 9 April 2021 - Oxford BioDynamics Plc (AIM: OBD,
the Company), a biotechnology company developing precision medicine
tests for personalized healthcare based on the EpiSwitch(R) 3D
genomics platform, has signed a lease agreement for new laboratory
and office space at Oxford Business Park , to significantly expand
its UK facilities.
The 24,000 sq ft premises will house the Company's growing UK
infrastructure, as it continues the execution of its expanded
strategic focus , announced in December 2020. The new lease follows
the recent launches of OBD's EpiSwitch (R) CST (Covid Severity
Test) and its EpiSwitch(R) Explorer Array Kit .
The larger space will allow OBD to operate independent
processing lines for commercial test development and product
support, biomarker discovery contracts, clinical trial support and
internal R&D projects. The new facility will also provide
custom-designed space for product manufacturing, sample and
consumables storage, as well as offices and meeting rooms to
accommodate the entire UK team.
Development work is expected to be completed in late July 2021.
Financial details were not disclosed.
Dr Jon Burrows, CEO of Oxford BioDynamics, said:
"This new lease comes at an exciting time for OBD, following the
launch of both our prognostic test for COVID-19 severity and the
EpiSwitch(R) Explorer Array Kit. It marks the next important step
of the continued roll-out of our expanded strategic focus.
"We moved into our current reference laboratory on the Oxford
Business Park in 2015 and expanded it in 2018; this new lease
reflects the next stage of our growth. We enjoy excellent support
from our landlord, Arlington, and the team at the Business Park. We
are very happy to be staying with them as we grow."
Daniel Williams, Development Director of Arlington, added:
"We are delighted to continue supporting the successful growth
of Oxford BioDynamics. Signing this new lease at Building 3140 is
testament to our customer-focused approach. With our commitment to
deliver the highest quality, flexible workspaces within an amenity
rich environment, our Life Science community is thriving. We look
forward to working with OBD for many more years to come."
-Ends-
FOR MORE INFORMATION:
Oxford BioDynamics Plc Tel: +44 (0)1865 518910
Jon Burrows, CEO
Paul Stockdale, CFO
Instinctif Partners Tel: +44 (0)20 7457 2020
Melanie Toyne-Sewell / Agnes Stephens OxfordBioDynamics@instinctif.com
/ Katie Duffell / Nathan Billis
NOTES TO EDITORS:
About Oxford BioDynamics Plc
Oxford BioDynamics Plc (AIM: OBD) is a global biotechnology
company, advancing personalized healthcare by developing and
commercializing precision medicine tests for life-changing
diseases.
The Company has developed a proprietary 3D genomic biomarker
platform, EpiSwitch(R), which can build molecular diagnostic
classifiers for prediction of response to therapy, patient
prognosis, disease diagnosis and subtyping, and residual disease
monitoring in a wide range of indications.
In March 2021, the Company launched its first commercial
prognostic test, EpiSwitch (R) CST (Covid Severity Test) and the
first commercially available microarray kit for high-resolution 3D
genome profiling and biomarker discovery, EpiSwitch(R) Explorer
Array Kit . Its next product will be a predictive immune response
profile for immuno-oncology (IO) checkpoint inhibitor treatments,
to be launched later in 2021.
Oxford BioDynamics has participated in more than 40 partnerships
with big pharma and leading institutions including Pfizer, EMD
Serono, Genentech, Roche, Biogen, Mayo Clinic, Massachusetts
General Hospital and Mitsubishi Tanabe Pharma.
The Company has created a valuable technology portfolio,
including biomarker arrays, molecular diagnostic tests,
bioinformatic tools for 3D genomics and an expertly curated 3D
genome knowledgebase comprising hundreds of millions of data points
from over 10,000 samples in more than 30 human diseases.
OBD is headquartered in Oxford, UK and is listed on AIM of the
London Stock Exchange. It also has a commercial team in the US and
a reference laboratory in Penang, Malaysia
For more information, please visit the Company's website,
www.oxfordbiodynamics.com , or follow on Twitter or LinkedIn .
About EpiSwitch(R)
The 3D configuration of the genome plays a crucial role in gene
regulation. By mapping this architecture and identifying abnormal
configurations, EpiSwitch(R) can be used to diagnose patients or
determine how individuals might respond to a disease or
treatment.
Built on over 10 years of research, EpiSwitch(R) is Oxford
Biodynamics' award-winning, proprietary platform that enables
screening, evaluation, validation and monitoring of 3D genomic
biomarkers. The technology is fully developed, based on testing of
over 10,000 samples in 30 disease areas, and reduced to
practice.
In addition to stratifying patients with respect to anticipated
clinical outcome, EpiSwitch(R) data offer insights into systems
biology and the physiological manifestation of disease that are
beyond the scope of other molecular modalities. The technology has
performed well in academic medical research settings and has been
validated through its integration in biomarker discovery and
clinical development with big pharma.
Oxford BioDynamics is leveraging its technology to develop a
pipeline of tests in a wide range of indications, such as
immuno-oncology, neurodegenerative and autoimmune diseases, to
follow its commercial EpiSwitch (R) CST (Covid Severity Test).
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAFFFFLSDITIIL
(END) Dow Jones Newswires
April 09, 2021 02:00 ET (06:00 GMT)
Oxford Biodynamics (LSE:OBD)
Historical Stock Chart
From Mar 2024 to Apr 2024
Oxford Biodynamics (LSE:OBD)
Historical Stock Chart
From Apr 2023 to Apr 2024